Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
COSMOS PharmaceuticalCSMYF 93 Receivables Turnover is 339.23 as of Feb. 2026. GuruFocus rates CSMYF with a GF Score™ of 93/100 and a GF Value™ of $51.79 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 657 Healthcare Providers & Services companies, COSMOS Pharmaceutical ranks better than 99.39% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. COSMOS Pharmaceutical's Revenue for the
three
months ended in Feb. 2026 was $1,761 Mil. COSMOS Pharmaceutical's average Accounts Receivable for the
three
months ended in Feb. 2026 was $5 Mil.
Hence, COSMOS Pharmaceutical's Receivables Turnover for the
three
months ended in Feb. 2026 was 339.23.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
COSMOS Pharmaceutical Receivables Turnover Related Terms
COSMOS Pharmaceutical Receivables Turnover Historical Data
* Premium members only.
The historical data trend for COSMOS Pharmaceutical's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, COSMOS Pharmaceutical's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
COSMOS Pharmaceutical Receivables Turnover vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, COSMOS Pharmaceutical's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where COSMOS Pharmaceutical's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COSMOS Pharmaceutical (CSMYF) has a Receivables Turnover of 339.23 as of Feb. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on COSMOS Pharmaceutical and its competitors. According to the industry distribution chart, COSMOS Pharmaceutical ranks #4 out of 657 companies in the Healthcare Providers & Services industry, placing it in the top 0.59999999999999%.
Is COSMOS Pharmaceutical's Receivables Turnover too high?
COSMOS Pharmaceutical's current Receivables Turnover is 339.23. The Healthcare Providers & Services industry median Receivables Turnover is 7.74. COSMOS Pharmaceutical's value of 339.23 is 4282.8% above this industry median. Based on the distribution chart, COSMOS Pharmaceutical ranks #4 out of 657 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, COSMOS Pharmaceutical has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does COSMOS Pharmaceutical's Receivables Turnover compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, COSMOS Pharmaceutical ranks #4 out of 657 companies for Receivables Turnover. This places COSMOS Pharmaceutical in the top 1% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 7.74. COSMOS Pharmaceutical's value of 339.23 is 4282.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Healthcare Providers & Services company?
The median Receivables Turnover among Healthcare Providers & Services companies is 7.74, based on 657 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. COSMOS Pharmaceutical's current Receivables Turnover of 339.23 is 4282.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on COSMOS Pharmaceutical and its competitors. For the Healthcare Providers & Services industry, the median Receivables Turnover is 7.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. COSMOS Pharmaceutical's current Receivables Turnover is 339.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is COSMOS Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, COSMOS Pharmaceutical (CSMYF) is currently considered Modestly Undervalued. The stock's GF Value™ is $51.79, compared to a current price of $37.06 — trading 28.4% below its estimated fair value. The current Receivables Turnover is 339.23 and 4282.8% above the Healthcare Providers & Services industry median of 7.74. COSMOS Pharmaceutical's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For COSMOS Pharmaceutical (CSMYF), the current Receivables Turnover is 339.23 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is COSMOS Pharmaceutical (CSMYF) Overvalued in 2026?
Based on GuruFocus' analysis, COSMOS Pharmaceutical stock appears to be undervalued.
The current stock price of $37.06 is trading 28.4% below its estimated GF Value™ of $51.79.
GuruFocus considers COSMOS Pharmaceutical to be Modestly Undervalued.
Key valuation signals for CSMYF:
Receivables Turnover: 339.23
GF Value™: $51.79 vs. price of $37.06 (28.4% below fair value)
Industry Position: 4282.8% above the Healthcare Providers & Services median (#4 of 657)
No single metric tells the full story. See the CSMYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
COSMOS Pharmaceutical Corp manages retail drugstores in Japan. The company emphasizes convenience regarding its product selection, which includes medical products, health and beauty aids, personal-care items, discount cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, alcoholic beverages, tobacco, insect repellent, and miscellaneous everyday consumables. The majority of the company's revenue is derived from common grocery sales. It also operates a private grocery brand called ON 365.
93GF Score
Get the complete analysis for CSMYF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSMYF has been successfully added to your 
